Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 2/20 | 0.33 |
| ▸ | F12 | P00748 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818848 | 0.83 | BCHE (0.48) | BCHECCKBRF12MEN1ALDH1A1 | |
| SCHEMBL6045967 | 0.83 | BCHE (0.48) | BCHECCKBRF12 | |
| SCHEMBL20570921 | 0.83 | BCHE (0.57) | BCHECCKBRF12 | |
| SCHEMBL27403754 | 0.80 | BCHE (0.65) | BCHEF12 | |
| SCHEMBL5536672 | 0.80 | BCHE (0.52) | BCHECCKBR | |
| SCHEMBL7692638 | 0.79 | BCHE (0.64) | BCHEF12 | |
| SCHEMBL10841290 | 0.79 | BCHE (0.44) | BCHECCKBRF12MEN1ALDH1A1 | |
| SCHEMBL3693863 | 0.79 | BCHE (0.44) | BCHECCKBRF12MEN1KMT2A | |
| SCHEMBL6332268 | 0.79 | BCHE (0.44) | BCHECCKBRF12 | |
| SCHEMBL6648615 | 0.79 | BCHE (0.50) | BCHECCKBRF12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, CNR1 | BCHE 1045/4885CCKBR 36/4885F12 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.